Aerie’s Anido Praises FDA Consistency
Vince Anido, PhD, CEO and chairman, Aerie Pharmaceuticals, sees hopeful signs in the FDA’s process to review combination therapies. This positioning could benefit Aerie in obtaining approval for Roclatan and Rhopressa, the company’s flagship wet age-related macular degeneration (AMD) products.
Participant:
Vicente Anido Jr., PhD
Vicente Anido, Jr., PhD currently serves as CEO and Chairman of the Board of Aerie Pharmaceuticals, Inc., a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.